187 related articles for article (PubMed ID: 18631009)
1. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma.
Shakir MK; Krook LS; Schraml FV; Hays JH; Clyde PW
Thyroid; 2008 Jul; 18(7):787-92. PubMed ID: 18631009
[TBL] [Abstract][Full Text] [Related]
2. Severe hyponatremia following radioactive iodine therapy in patients with differentiated thyroid cancer.
Kim SK; Yun GY; Kim KH; Park SK; Choi HY; Ha SK; Park HC
Thyroid; 2014 Apr; 24(4):773-7. PubMed ID: 24093878
[TBL] [Abstract][Full Text] [Related]
3. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma.
Horie I; Ando T; Imaizumi M; Usa T; Kawakami A
Endocr Pract; 2015 May; 21(5):488-94. PubMed ID: 25667379
[TBL] [Abstract][Full Text] [Related]
4. Biochemical Effects of Levothyroxine Withdrawal in Patients with Differentiated Thyroid Cancer.
Papadakis G; Kalaitzidou S; Triantafillou E; Drosou A; Kakava K; Dogkas N; Pappa T; Kaltzidou V; Tertipi A; Villiotou V; Pappas A
Anticancer Res; 2015 Dec; 35(12):6933-40. PubMed ID: 26637919
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
Pacini F; Castagna MG
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
7. Severe hyponatremia: a comorbidity with I131 therapy in a patient with papillary thyroid cancer.
Kaewput C; Pusuwan P
J Med Assoc Thai; 2014 Aug; 97(8):886-90. PubMed ID: 25345266
[TBL] [Abstract][Full Text] [Related]
8. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.
Luster M; Felbinger R; Dietlein M; Reiners C
Thyroid; 2005 Oct; 15(10):1147-55. PubMed ID: 16279848
[TBL] [Abstract][Full Text] [Related]
9. [Increase in TSH levels in thyroid carcinoma patients after withdrawal of suppressive levothyroxine medication].
Hackländer S; Voth E; Schicha H
Nuklearmedizin; 1996 Oct; 35(5):170-4. PubMed ID: 9005413
[TBL] [Abstract][Full Text] [Related]
10. Severe hyponatremia in association with I(131) therapy in a patient with metastatic thyroid cancer.
Nozu T; Yoshida Y; Ohira M; Okumura T
Intern Med; 2011; 50(19):2169-74. PubMed ID: 21963736
[TBL] [Abstract][Full Text] [Related]
11. Papillary thyroid carcinoma metastatic to the pituitary gland.
Masiukiewicz US; Nakchbandi IA; Stewart AF; Inzucchi SE
Thyroid; 1999 Oct; 9(10):1023-7. PubMed ID: 10560958
[TBL] [Abstract][Full Text] [Related]
12. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
[TBL] [Abstract][Full Text] [Related]
13. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
14. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma.
Botella-Carretero JI; Gómez-Bueno M; Barrios V; Caballero C; García-Robles R; Sancho J; Escobar-Morreale HF
Endocr Relat Cancer; 2004 Jun; 11(2):345-56. PubMed ID: 15163309
[TBL] [Abstract][Full Text] [Related]
15. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
16. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
17. RENAL FUNCTION AND PLASMA RENIN ACTIVITY AS POTENTIAL FACTORS CAUSING HYPERKALEMIA IN PATIENTS WITH THYROID CARCINOMA UNDERGOING THYROID HORMONE WITHDRAWAL FOR RADIOACTIVE IODINE THERAPY.
Niri T; Horie I; Ando T; Kawahara H; Ueda M; Eto M; Sako A; Ikeuchi Y; Nakao T; Nakashima Y; Shigeno R; Ito A; Nozaki A; Haraguchi A; Natsuda S; Sagara I; Akazawa S; Kamada A; Imaizumi M; Abiru N; Usa T; Kawakami A
Endocr Pract; 2020 Feb; 26(2):197-206. PubMed ID: 31652100
[No Abstract] [Full Text] [Related]
18. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation.
Iakovou I; Goulis DG; Tsinaslanidou Z; Giannoula E; Katsikaki G; Konstantinidis I
Head Neck; 2016 Apr; 38 Suppl 1():E227-30. PubMed ID: 25537365
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
